PMA is the U.S. Food and Drug Administration premarket approval pathway for high-risk Class III medical devices that do not qualify for 510(k) substantial-equivalence review. In regulatory translation, it appears in clinical study reports, labeling, manufacturing summaries, and post-approval study documents, all of which must be filed in English for FDA review and updated through supplements when changes occur after approval.
PMA appears in U.S. regulatory submissions for high-risk devices, including clinical trial documents, patient labeling, and manufacturing site descriptions. Translators may support investigator-facing materials or summarize non-English clinical data into English sections, but must not alter efficacy or safety claims during summarization; the terminology also appears in post-approval study progress reports.
A frequent error is treating PMA as an extension of 510(k) or translating 'approval' loosely in a way that implies broader marketing authorization than the FDA granted. This can misstate the device’s approved indications and create compliance risk if promotional or labeling text is not limited to the PMA-approved claims and conditions.
FDA, CE/MDR and NMPA reviewers assess the submitted wording itself. Regulatory bodies require traceable, accountable translation, and an inconsistent term can delay or fail a submission.
Angel Translation locks terms like this into a project terminology base before expert review begins, so the same source term resolves to the same target term across every document in a submission — and stays consistent in the next revision. See the 8-step AI + expert workflow.
Send us the files. Acknowledged in 4 hours, quoted in 24.
Request a Quote →Life Science solutions →